Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women

Clinical trials have demonstrated that adding zoledronic acid (Zol) to (neo)adjuvant standard of care has differential antitumour effects in pre- and post-menopausal women: Both benefit from reduced recurrence in bone; however, while postmenopausal women also incur survival benefit, none is seen in...

Descripción completa

Detalles Bibliográficos
Autores principales: Canuas-Landero, Victor G., George, Christopher N., Lefley, Diane V., Corness, Hannah, Muthana, Munitta, Wilson, Caroline, Ottewell, Penelope D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559775/
https://www.ncbi.nlm.nih.gov/pubmed/34733240
http://dx.doi.org/10.3389/fendo.2021.749428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559775/
https://www.ncbi.nlm.nih.gov/pubmed/34733240
http://dx.doi.org/10.3389/fendo.2021.749428

Ejemplares similares